Trials / Withdrawn
WithdrawnNCT07030699
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Epcoritamab With Lenalidomide and Tafasitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL. This is the first time the combination of drugs is being tested.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epcoritamab | Subcutaneous, once weekly in cycles 1-3; every 4 weeks cycles 4-12 |
| DRUG | Lenalidomide | Oral, daily on days 1-21 of a 28-day cycle |
| DRUG | Tafasitamab | Intravenous, once weekly during cycles 1-3, then every 2 weeks during cycle 4-12 |
Timeline
- Start date
- 2025-08-13
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2025-06-22
- Last updated
- 2026-04-07
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07030699. Inclusion in this directory is not an endorsement.